Good afternoon :)
$
₹
IQVIA Holdings Inc

IQVIA Holdings Inc

IQV

NYSE
Asset Logo

IQVIA Holdings Inc

IQV

NYSE
$257.340.14% (+0.36)
$
₹
$257.340.14% (+0.36)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
Loading...
1D
1W
1M
1Y
5Y
Max

Healthcare

Diagnostics & Research

Large Cap

With a market cap of $42.2B the stock is ranked 377

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

31.91
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

7.14
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$8.04
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

0.97
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

8.1%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast
Analyst Ratings & Forecast

Based on 23 analysts' reports

Buy
16 analysts
Hold
7 analysts
Sell
0 analyst

Analysts expect a +7.51% price upside over the next year

Current Price$257.34
Target Price$276.27

Company Profile

IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and associated implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a strategic collaboration with Kexing Biopharm Co., Ltd. for biosimilar development. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. is based in Durham, North Carolina.
IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and associated implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a strategic collaboration with Kexing Biopharm Co., Ltd. for biosimilar development. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. is based in Durham, North Carolina.

Peers

Peers

Thermo Fisher Scientific Inc
TMO
Thermo Fisher Scientific Inc
P/E Ratio
32.42
32.42
1Y Return
26.68%
26.68%
Buy Reco %
80.64
80.64
Agilent Technologies Inc
A
Agilent Technologies Inc
P/E Ratio
28.96
28.96
1Y Return
15.53%
15.53%
Buy Reco %
82.35
82.35
Waters Corporation
WAT
Waters Corporation
P/E Ratio
102.48
102.48
1Y Return
37.06%
37.06%
Buy Reco %
31.81
31.81
Illumina Inc
ILMN
Illumina Inc
P/E Ratio
39.30
39.30
1Y Return
114.68%
114.68%
Buy Reco %
55.00
55.00
Mettler-Toledo International Inc
MTD
Mettler-Toledo International Inc
P/E Ratio
29.85
29.85
1Y Return
2.21%
2.21%
Buy Reco %
30.76
30.76

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareDiagnostics & Research

Valuation

Returns

Forecast

StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
IQVIA Holdings Inc 31.917.140.97
Thermo Fisher Scientific Inc32.424.301.82
Agilent Technologies Inc28.965.771.24

Price Comparison

Price Comparison

1 Month

1 Year

5 Years

Loading...

Financials

Financials

Income

Balance Sheet

Cash Flow

4.1
0.3
4.3
0.5
4.1
0.2
4.3
0.2
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
Financial YearQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Total Revenue3.733.813.893.953.824.014.14.364.154.36
Net Income0.280.360.280.430.240.260.330.510.270.25
Net Profit Margin7.70%9.51%7.31%11.04%6.50%6.62%8.07%11.77%6.60%5.86%
See CostsAll values in $ Billion

Frequently asked questions

Frequently asked questions

  1. IQVIA Holdings Inc (IQV) share price today is $257.34 as of September 11, 2026 at 1:30 AM IST. The stock touched a day high of $258.54 and a day low of $253.08.

  2. IQVIA Holdings Inc stock trades on NYSE under the ticker symbol IQV.

  3. IQVIA Holdings Inc's market capitalization is $42.24B as of September 11, 2026 at 1:30 AM IST.

  4. IQVIA Holdings Inc's price-to-earnings (P/E) ratio is 31.91 as of September 10, 2026.

  5. IQVIA Holdings Inc's price-to-book (P/B) ratio is 7.14 as of September 10, 2026.

  6. Yes, You can buy IQVIA Holdings Inc shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy IQVIA Holdings Inc shares in three steps: 1. Search IQVIA Holdings Inc on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since IQVIA Holdings Inc trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in IQVIA Holdings Inc (IQV) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 0.0388 shares at the current price of $257.34.

Loading...